Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your Child's nose bacteria may boost flu shot power

NCT ID NCT06609811

Knowledge-focused Sponsor: Jiangsu Province Centers for Disease Control and Prevention Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how bacteria living in the nose and gut influence the immune response to a nasal flu vaccine in 201 children aged 6 to 17. Half got the vaccine right away, half waited 28 days. Researchers collected samples before and after vaccination to measure antibodies and bacterial changes. The goal was to understand if these natural microbes help or hinder vaccine effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intranasal Influenza Live Attenuated Vaccine
What this could lead to
If successful, this could help design better flu vaccines by understanding how natural bacteria in the nose and gut influence immune protection.
What could go wrong
This is a completed Phase 4 study focused on observation, not testing a new treatment. Results may not lead to immediate changes in vaccine recommendations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

201 people

The number who actually took part.

Started

Sep 2024

Finished

Jan 2025

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 17 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Individuals aged 6-17 years. 2. Volunteers and their guardians are able and willing to comply with the requirements of the clinical trial protocol and sign the informed consent form. Exclusion Criteria: 1. Allergy to any component of the vaccine product, including eggs, excipients, or gentamicin sulfate. 2. Individuals with acute illnesses, severe chronic illnesses, acute exacerbations of chronic illnesses, or fever. 3. Pregnant or lactating women. 4. Individuals with Leigh syndrome who are receiving treatment with aspirin or aspirin-containing medications. 5. Individuals with immunodeficiency, immunosuppression, or those undergoing immunosuppressive therapy. 6. Individuals with uncontrolled epilepsy, other progressive neurological disorders, or a history of Guillain-Barré syndrome. 7. Individuals with rhinitis or asthma. 8. Individuals with a personal or family history of seizures, chronic diseases, epilepsy, or allergic tendencies. 9. Individuals who have received immunoglobulin injections within the last 3 months prior to vaccination. 10. Individuals who have used other live attenuated vaccines within 1 month prior to vaccination. 11. Individuals planning to use antiviral drugs for influenza within 48 hours before or 2 weeks after vaccination. 12. Individuals planning to use any other intranasal medication within 2 days after vaccination.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

influenza prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Influenza

Contacts and locations

Locations

  • Haizhou District Center for Disease Control and Prevention

    Lianyungang, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.